Silexion Therapeutics Ltd. cash flow to debt ratio of -2.31K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Silexion Therapeutics Ltd.'s free cash flow has decreased 28.63% from $-8.42M last year to $-10.83M, signaling decreasing performance

Silexion Therapeutics Ltd.'s debt to equity ratio is 1.50, which means that the company's assets are unhealthy financed, signaling financial risk.

Silexion Therapeutics Ltd.'s debt has increased relative to shareholder equity from -1.13 last year to 1.50 today, signaling weakened financials

Silexion Therapeutics Ltd. has a net cash position, so leverage is healthy.

Silexion Therapeutics Ltd. earns at least as much interest as it pays. Interest obligations are fully covered.

Silexion Therapeutics Ltd. has insufficient data to evaluate this check.

Silexion Therapeutics Ltd.'s short-term assets of $6.64M exceed its short-term liabilities of $2.76M

Silexion Therapeutics Ltd.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Silexion Therapeutics Ltd.'s return on equity of -516.87%, is lower than 15.00%, indicating bad performance

Silexion Therapeutics Ltd.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Silexion Therapeutics Ltd. has insufficient public price history to evaluate earnings stability.

Silexion Therapeutics Ltd. has negative free cash flow, indicating the company is burning cash rather than generating it

Silexion Therapeutics Ltd. has negative free cash flow, indicating cash burn

Silexion Therapeutics Ltd.'s yearly earnings has increased -27.56% since last year from $-16.44M to $-11.91M, signaling increasing performance

Silexion Therapeutics Ltd.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC 1.45K% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Silexion Therapeutics Ltd. has insufficient revenue history to calculate 3-year revenue CAGR.

Silexion Therapeutics Ltd. has insufficient public price history to evaluate revenue consistency.

Silexion Therapeutics Ltd. has insufficient public price history to evaluate ROE consistency.

Silexion Therapeutics Ltd. has insufficient data to evaluate this check.

Silexion Therapeutics Ltd. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Silexion Therapeutics Ltd. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Silexion Therapeutics Ltd. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Silexion Therapeutics Ltd. has insufficient data to evaluate this check.

Silexion Therapeutics Ltd. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Silexion Therapeutics Ltd. has a price-to-book ratio of 1.67x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Silexion Therapeutics Ltd. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue